Summary
The 2-year results from the Endovascular Valve Edge-to-Edge Repair trial [EVEREST II; NCT00209274] showed that percutaneous mitral valve repair is safe and durable with measurable clinical benefits and is a therapeutic option for select patients with significant mitral regurgitation [Feldman T et al. N Engl J Med 2011].
- Valvular Disease
- Interventional Techniques & Devices Clinical Trials
- © 2011 MD Conference Express
Tools
EVEREST Trial 2-Year Results Show Stability of Percutaneous MV Repair between Years 1 and 2
Permalink:
Table of contents
Cited By...
- No citing articles found.